Skandinaviska Enskilda Banken Ab (Publ) Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $7.6 Million - $7.99 Million	-52,454 Reduced 99.82%	92 $14,000
Q2 2022 Aug 10, 2022	SELL	$83.14 - $145.99 $6.54 Million - $11.5 Million	-78,640 Reduced 59.95%	52,546 $7.66 Million
Q1 2022 May 11, 2022	SELL	$110.08 - $142.92 $2.63 Million - $3.42 Million	-23,914 Reduced 15.42%	131,186 $15.6 Million
Q4 2021 Feb 10, 2022	SELL	$99.73 - $148.48 $1.93 Million - $2.87 Million	-19,318 Reduced 11.08%	155,100 $21.4 Million
Q3 2021 Nov 10, 2021	SELL	$98.85 - $138.91 $303,963 - $427,148	-3,075 Reduced 1.73%	174,418 $24.2 Million
Q2 2021 Aug 10, 2021	BUY	$65.78 - $105.02 $3.81 Million - $6.09 Million	57,957 Added 48.48%	177,493 $17.2 Million
Q1 2021 May 14, 2021	BUY	$64.07 - $91.75 $7.66 Million - $11 Million	119,536 New	119,536 $8.17 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.